Unfavorable prognostic factors in SM by univariate analysis
| Prognostic factor . | No. of patients . | No. of deaths . | Median survival, mo . | P, log-rank test . |
|---|---|---|---|---|
| Age, y | ||||
| Younger than 65 | 222 | 64 | 163 | < .001 |
| 65 or older | 120 | 89 | 24 | |
| Sex | ||||
| Female | 154 | 60 | 136 | .001 |
| Male | 188 | 93 | 45 | |
| WHO variant | ||||
| ISM | 159 | 26 | 198 | < .001 |
| ASM | 41 | 25 | 41 | |
| SM-AHNMD | 138 | 99 | 24 | |
| MCL | 4 | 3 | 2 | |
| Symptoms and signs | ||||
| Urticaria pigmentosa | ||||
| No | 202 | 113 | 34 | < .001 |
| Yes | 140 | 40 | 163 | |
| Cutaneous symptoms* | ||||
| No | 160 | 95 | 34 | < .001 |
| Yes | 182 | 58 | 146 | |
| Constitutional symptoms† | ||||
| No | 200 | 57 | 145 | < .001 |
| Yes | 142 | 96 | 20 | |
| Mediator-related symptoms‡ | ||||
| No | 182 | 103 | 41 | < .001 |
| Yes | 160 | 50 | 146 | |
| Weight loss | ||||
| No | 224 | 67 | 136 | < .001 |
| Yes | 118 | 86 | 17 | |
| Splenomegaly§ | ||||
| No | 212 | 60 | 156 | < .001 |
| Yes | 123 | 88 | 25 | |
| Hepatomegaly§ | ||||
| No | 250 | 87 | 96 | < .001 |
| Yes | 92 | 66 | 30 | |
| Lymphadenopathy§ | ||||
| No | 269 | 109 | 82 | .005 |
| Yes | 73 | 44 | 38 | |
| Laboratory findings | ||||
| Anemia | ||||
| No | 186 | 45 | 165 | < .001 |
| Yes | 155 | 108 | 20 | |
| Thrombocytopenia | ||||
| No | 233 | 70 | 136 | < .001 |
| Yes | 101 | 78 | 15 | |
| Leukocytosis | ||||
| No | 231 | 82 | 136 | < .001 |
| Yes | 109 | 71 | 25 | |
| Absolute eosinophil count 1.5 × 109/L or more | ||||
| No | 283 | 115 | 75 | < .001 |
| Yes | 49 | 34 | 18 | |
| PB immature myeloid cells | ||||
| No | 244 | 79 | 136 | < .001 |
| Yes | 89 | 71 | 13 | |
| Ferritin level > 300 μg/L | ||||
| No | 58 | 25 | 66 | < .001 |
| Yes | 47 | 36 | 17 | |
| SAP > UNL | ||||
| No | 191 | 66 | 119 | < .001 |
| Yes | 127 | 81 | 24 | |
| AST > UNL | ||||
| No | 283 | 123 | 69 | .004 |
| Yes | 37 | 22 | 24 | |
| Hypoalbuminemia§ | ||||
| No | 215 | 98 | 82 | < .001 |
| Yes | 50 | 34 | 12 | |
| LDH > UNL | ||||
| No | 136 | 60 | 57 | .008 |
| Yes | 28 | 20 | 20 | |
| Total bilirubin > 18.8 μM/L | ||||
| No | 237 | 101 | 82 | < .001 |
| Yes | 55 | 41 | 15 | |
| Serum tryptase level > 200 ng/mL | ||||
| No | 127 | 20 | 136 | < .001 |
| Yes | 33 | 19 | 30 | |
| Bone marrow findings | ||||
| BM cellularity§ | ||||
| Low | 19 | 1 | NR | < .001 |
| Normal | 108 | 13 | 295 | |
| High§ | 200 | 128 | 30 | |
| BM MC 30% or more§ | ||||
| No | 235 | 82 | 96 | < .001 |
| Yes | 64 | 45 | 30 | |
| BM blasts 5% or more | ||||
| No | 315 | 131 | 72 | < .001 |
| Yes | 27 | 22 | 11 | |
| BM fibrosis grade 2+ or more | ||||
| No | 78 | 41 | 61 | < .001 |
| Yes | 44 | 32 | 18 | |
| Karyotype | ||||
| Normal | 144 | 68 | 53 | .002 |
| Abnormal | 42 | 33 | 13 |
| Prognostic factor . | No. of patients . | No. of deaths . | Median survival, mo . | P, log-rank test . |
|---|---|---|---|---|
| Age, y | ||||
| Younger than 65 | 222 | 64 | 163 | < .001 |
| 65 or older | 120 | 89 | 24 | |
| Sex | ||||
| Female | 154 | 60 | 136 | .001 |
| Male | 188 | 93 | 45 | |
| WHO variant | ||||
| ISM | 159 | 26 | 198 | < .001 |
| ASM | 41 | 25 | 41 | |
| SM-AHNMD | 138 | 99 | 24 | |
| MCL | 4 | 3 | 2 | |
| Symptoms and signs | ||||
| Urticaria pigmentosa | ||||
| No | 202 | 113 | 34 | < .001 |
| Yes | 140 | 40 | 163 | |
| Cutaneous symptoms* | ||||
| No | 160 | 95 | 34 | < .001 |
| Yes | 182 | 58 | 146 | |
| Constitutional symptoms† | ||||
| No | 200 | 57 | 145 | < .001 |
| Yes | 142 | 96 | 20 | |
| Mediator-related symptoms‡ | ||||
| No | 182 | 103 | 41 | < .001 |
| Yes | 160 | 50 | 146 | |
| Weight loss | ||||
| No | 224 | 67 | 136 | < .001 |
| Yes | 118 | 86 | 17 | |
| Splenomegaly§ | ||||
| No | 212 | 60 | 156 | < .001 |
| Yes | 123 | 88 | 25 | |
| Hepatomegaly§ | ||||
| No | 250 | 87 | 96 | < .001 |
| Yes | 92 | 66 | 30 | |
| Lymphadenopathy§ | ||||
| No | 269 | 109 | 82 | .005 |
| Yes | 73 | 44 | 38 | |
| Laboratory findings | ||||
| Anemia | ||||
| No | 186 | 45 | 165 | < .001 |
| Yes | 155 | 108 | 20 | |
| Thrombocytopenia | ||||
| No | 233 | 70 | 136 | < .001 |
| Yes | 101 | 78 | 15 | |
| Leukocytosis | ||||
| No | 231 | 82 | 136 | < .001 |
| Yes | 109 | 71 | 25 | |
| Absolute eosinophil count 1.5 × 109/L or more | ||||
| No | 283 | 115 | 75 | < .001 |
| Yes | 49 | 34 | 18 | |
| PB immature myeloid cells | ||||
| No | 244 | 79 | 136 | < .001 |
| Yes | 89 | 71 | 13 | |
| Ferritin level > 300 μg/L | ||||
| No | 58 | 25 | 66 | < .001 |
| Yes | 47 | 36 | 17 | |
| SAP > UNL | ||||
| No | 191 | 66 | 119 | < .001 |
| Yes | 127 | 81 | 24 | |
| AST > UNL | ||||
| No | 283 | 123 | 69 | .004 |
| Yes | 37 | 22 | 24 | |
| Hypoalbuminemia§ | ||||
| No | 215 | 98 | 82 | < .001 |
| Yes | 50 | 34 | 12 | |
| LDH > UNL | ||||
| No | 136 | 60 | 57 | .008 |
| Yes | 28 | 20 | 20 | |
| Total bilirubin > 18.8 μM/L | ||||
| No | 237 | 101 | 82 | < .001 |
| Yes | 55 | 41 | 15 | |
| Serum tryptase level > 200 ng/mL | ||||
| No | 127 | 20 | 136 | < .001 |
| Yes | 33 | 19 | 30 | |
| Bone marrow findings | ||||
| BM cellularity§ | ||||
| Low | 19 | 1 | NR | < .001 |
| Normal | 108 | 13 | 295 | |
| High§ | 200 | 128 | 30 | |
| BM MC 30% or more§ | ||||
| No | 235 | 82 | 96 | < .001 |
| Yes | 64 | 45 | 30 | |
| BM blasts 5% or more | ||||
| No | 315 | 131 | 72 | < .001 |
| Yes | 27 | 22 | 11 | |
| BM fibrosis grade 2+ or more | ||||
| No | 78 | 41 | 61 | < .001 |
| Yes | 44 | 32 | 18 | |
| Karyotype | ||||
| Normal | 144 | 68 | 53 | .002 |
| Abnormal | 42 | 33 | 13 |
No. indicates number; ISM indicates indolent systemic mastocytosis (SM); ASM, aggressive SM; SM-AHNMD, SM with associated clonal hematologic non–mast cell lineage disease; MCL, mast cell leukemia; dL, deciliter; L, liter; UNL upper normal limit; μg, micrograms; mg, milligrams; ng, nanograms; AST, aspartate transaminase; SAP, serum alkaline phosphatase; LDH, lactate dehydrogenase; BM, bone marrow; MC, mast cell; and NR, not reached.
Includes pruritus, flushing, urticaria, and angioedema.
Includes weight loss, fever, chills, and night sweats.
Includes headache, dizziness/lightheadedness, syncope/presyncope, hypotension, anaphylaxis, palpitation/tachycardia, bronchoconstriction/wheezing, and peptic ulcer disease.
Represent B- or C-findings per the 2001 WHO classification of SM.